Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, bezlotoxumab (Zinplava®) cannot be endorsed for use within NHS Wales for the prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI. |
||
|
||
Medicine details |
||
| Medicine name | bezlotoxumab (Zinplava®) | |
| Formulation | 25 mg/ml concentrate for solution for infusion | |
| Reference number | 3034 | |
| Indication | For the prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI. |
|
| Company | Merck Sharp & Dohme Ltd | |
| BNF chapter | Infections | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 25/07/2017 | |